The initial public offering (IPO) of Senores Pharmaceuticals Ltd has concluded with a subscription of 93.69 times across categories; NIIs, QIBs, RIIs, and Employees quotas. An 8.5 crore issue, received bids for a staggering 79,95,96,646 shares against 85,34,681 shares. In terms of category, The Non-Institutional Investors and Qualified Institutional Buyers (QIBs) have participated the most following Retail Individual Investors (RIIs) and Employees portion.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

Ahead of opening the IPO, Senores Pharmaceuticals secured Rs 261 crore from anchor investors.

Category-wise subscription details

Here is how the category-wise Senores Pharma IPO fared:

Non-Institutional Investors: 96.30 times subscribed to 22,33,98,732 shares against 23,19,879 shares allocated for them

Qualified Institutional Buyers (QIBs): 94.66 times subscribed to 43,47,78,102 shares against 45,93,216 shares reserved for them

Retail Investors: 90.46 times subscribed to 13,99,04,334 shares against 15,46,586 shares

Employees portion: It garners subscription of 20.21 times or 15,15,478 shares against 75,000 shares

Senores Pharma IPO allotment, listing details; know how to check the status online

After the closing of the bidding process applicants search for allotment, listing details like dates, and registrar. The allotment date of the Senores Pharma IPO is December 26, 2024. Here is a step-by-step guide to check your allotment status for Senores Pharma IPO via the registrar's website:

  • Visit the official registrar website of Link Intime India Pvt Ltd — linkintime.co.in/initial_offer/public-issues.html
  • Select the IPO company, Senores Pharmaceuticals Ltd
  • Fill in the details of your PAN card/application number/demat account/account no and IFSC.
  • Click on the 'Submit' button, and the status of your application will appear.

Senores Pharma listing date

The Senores Pharma stock will be listed on the NSE and BSE exchanges on December 30, 2024.

About the pharma sector company

Senores Pharmaceuticals Ltd (SPL) is a global drug maker that develops and manufactures underpenetrated and complex products across different therapeutic areas and dosage forms. It also operates in the critical care injectables segment.